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Disease-Causing Mutations in Genes of the
Complement System
Søren E. Degn,1,* Jens C. Jensenius,1 and Steffen Thiel1,*Recent studies have revealed profound developmental conse-
quences of mutations in genes encoding proteins of the lectin
pathway of complement activation, a central component of the
innate immune system. Apart from impairment of immunity
against microorganisms, it is known that hereditary deficiencies
of this system predispose one to autoimmune conditions. Poly-
morphisms in complement genes are linked to, for example,
atypical hemolytic uremia and age-dependent macular degenera-
tion. The complement system comprises three convergent path-
ways of activation: the classical, the alternative, and the lectin
pathway. The recently discovered lectin pathway is less studied,
but polymorphisms in the plasma pattern-recognition molecule
mannan-binding lectin (MBL) are known to impact its level,
and polymorphisms in the MBL-associated serine protease-2
(MASP-2) result in defects of complement activation. Recent
studies have described roles outside complement and immunity
of another MBL-associated serine protease, MASP-3, in the
etiology of 3MC syndrome, an autosomal-recessive disorder
involving a spectrum of developmental features, including charac-
teristic facial dysmorphism. Syndrome-causing mutations were
identified in MASP1, encoding MASP-3 and two additional
proteins, MASP-1 and MAp44. Furthermore, an association was
discovered between 3MC syndrome and mutations in COLEC11,
encoding CL-K1, another molecule of the lectin pathway. The
findings were confirmed in zebrafish, indicating that MASP-3
and CL-K1 underlie an evolutionarily conserved pathway of
embryonic development. Along with the discovery of a role of
C1q in pruning synapses in mice, these recent advances point
toward a broader role of complement in development. Here, we
compare the functional immunologic consequences of ‘‘conven-
tional’’ complement deficiencies with these newly described
developmental roles.
Complement System and Components
As a prelude to discussing the polymorphisms and genetics
of the complement system, we wish to set the stage with
a brief introduction to the complement pathways and
the proteins involved.
The complement system is the humoral backbone of the
innate immune defense. It is thus involved in a number of
diverse processes involving antimicrobial defense, clear-
ance of immune complexes, and tissue regeneration. The
system comprises more than 35 humoral and cell-associ-
ated proteins forming three converging enzymatic
cascades: the classical pathway, the alternative pathway,
and the lectin pathway.1 An overview is shown in Figure 1,
where some of the proteins mentioned in the following are
placed in their context.1Department of Medical Microbiology and Immunology, Aarhus University, W
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The AmeThe classical pathway is especially important for control
of infections with pyogenic encapsulated bacteria, such as
Haemophilus influenzae and Streptococcus pneumoniae,2
although it has also been implicated in control of viral
infections, such as influenza.3 The pathway is initiated
when the recognition protein C1q binds to antibodies
bound tomicrobes or in immune complexes.2,4 Preexisting
‘‘natural IgM’’ produced by naive B cells5 and IgM or IgG
generated through an adaptive response (primary or
secondary) will bind to, for example, determinants on
the capsule of pathogenic bacteria, leading to agglutina-
tion. Binding of IgM exposes cryptic binding sites on
IgM, allowing C1q to bind, and binding of arrays of IgG
similarly allows high-avidity binding of C1q. C1q is in
complex with two serine proteases, C1r and C1s. Upon
binding of C1q, conformational changes lead to autoacti-
vation of C1r, which in turn activates C1s. Activated C1s
is capable of cleaving C4 and C2. A fragment of C4, C4b,
is deposited on the activating surface, where it is cova-
lently attached through a reactive thioester, while a small
fragment, C4a, is released. The proenzyme C2 is likewise
cleaved by C1s into two fragments, and C2a joins C4b
on the surface. C2a is a serine protease, capable of cleaving
C3. Cleaved C3 in the form of C3b is covalently bound to
the surface-attached C4bC2a complex, while the concom-
itantly generated small fragment C3a is released to medi-
ate inflammation. C2a in the newly formed complex,
C4bC2aC3b, is now able to cleave C5, and two fragments
are again generated: C5a is a potent inflammatory medi-
ator, while C5b initiates the formation of a membrane
attack complex (MAC), which is expanded through depo-
sition of C6, C7, C8 and C9 (Figure 1), leading to the
formation of a hole in the target cell membrane. More
importantly, the deposited components C4b and C3b
function as molecular tags (opsonins) interacting with
complement receptors, hereby facilitating engulfment by
phagocytes and activation of B cells.
The lectin pathway is quite similar to the classical
pathway.6 An overview of the components of this pathway
and the structure of some of the proteins is presented in
Figure 2. The lectin pathway is also involved mainly in
the control of bacterial infections, as has been observed
in the case of children suffering from recurrent pyogenic
infections.2,7 It would appear that the lectin pathway is
especially important during the interval between the lossilhelm Meyers Alle´ 4, 8000 Aarhus C, DK-Denmark
(S.T.)
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Figure 1. Overview of the Complement Pathways
The three activating pathways and the terminal pathway are
shown. The acronyms of participating proteins are given. The
lectin pathway is activated when MBL or ficolins in complex
with MASPs recognize foreign patterns of carbohydrate or acetyl
groups. The classical pathway is activated by C1q in complex
with C1s and C1r upon binding of antibody-antigen complexes.
The alternative pathway is constitutively activated and inhibited
on self-surfaces, but is allowed to proceed on foreign surfaces.
The three pathways converge on C3 and C5 and the common
terminal pathway leading to formation of the membrane attack
complex.of passively acquired maternal antibody and the acquisi-
tion of a mature immunologic repertoire, as well as in
individuals with immunosuppression. The pathway is
initiated when one or more recognition molecules bind
to patterns of carbohydrates or patterns of acetyl groups
on the surface of, for example, bacteria or viruses. Four
such recognition molecules are capable of activating the
lectin pathway: mannan-binding lectin (MBL), H-ficolin,
L-ficolin, and M-ficolin.8 These pattern-recognition
molecules (PRMs) are found in complexes with three
serine proteases (termed MBL-associated serine proteases
[MASPs]), MASP-1, MASP-2, and MASP-3, as well as two
nonenzymatic fragments hereof (termed MBL-associated
proteins), MAp19 and MAp44 (Figure 2A). When one of
the recognition molecules binds to an adequate pattern,
the MASPs are activated. MASP-1 and MASP-2 are respon-
sible for complement activation through cleavage of C2
and C4 (Figure 2B).9 The cascade then proceeds as
described above for the classical pathway.
Recently, a fifth PRM, CL-K1,10 was reported to associate
with MASPs.11 Although it reportedly binds to various
pathogen-associated molecular patterns (PAMPs), it re-
mains to be determined whether CL-K1 can activate
complement.
Whereas MASP-1 and MASP-2 have been described to be
true enzymes with defined substrates, MASP-3, MAp19,
and MAp44 have been suggested to act as regulators of
complement activation,12–14 but the relevance of these690 The American Journal of Human Genetics 88, 689–705, June 10,in vitro observations remains unknown. The surprising
new findings of potential functions of MASP-3 and CL-
K1 are described in detail below.
The third way of activating complement, the alternative
pathway, is also presented in Figure 1. In many regards,
this pathway can be described as an amplification mecha-
nism, because it is always activated after activation by the
classical and the lectin pathways. Thus, the alternative
pathway is important for the activity of the classical and
lectin pathways. When the C3b fragment is bound to
a surface (see above) it forms a complex with factor B.
This leads to the cleavage of factor B by factor D, giving
rise to an active enzyme complex with the fragment Bb
as the enzyme. The substrate for Bb is C3, and efficient
deposition of more C3b fragments occurs onto nearby
surfaces, again giving rise to even more complex forma-
tions. In analogy with C2a, the active Bb enzyme may
now also cleave C5 and thus generate all of the functions
described above.
In addition to its function as an amplification mecha-
nism of the classical and the lectin pathway, the alternative
pathway may be initiated when C3 in plasma is spontane-
ously activated through hydrolysis of an internal thioester
(so-called ‘‘tick-over’’). This spontaneous event occurs at
a constant low rate wherever in the body C3 is present
(blood and interstitial fluids) and is an effect of small
perturbations of a somewhat unstable structure of C3,
exposing the internal thioester to the solvent.15,16 Thus,
generated C3(H2O) can form a complex with factor B,
leading to cleavage of factor B by factor D and thus the
formation of a C3-activating complex, C3(H2O)Bb, which
upon further cleavage and addition of C3 forms a C5-acti-
vating complex, C3(H2O)BbC3b. The alternative pathway
and the terminal lytic pathway are especially important
for control of Neisserial infections, particularly Neisseria
meningitidis.2
Plasma and cell surfaces harbor regulators of comple-
ment activation (e.g., factor H and CD59, respectively),
immediately causing a local shutdown of the cascade,
thus leaving host cells unharmed. On a foreign surface,
which does not contain such regulators, the cascade
continues undisturbed, ending with opsonization of the
target and the formation of membrane-spanning MAC
complexes. The regulators of complement activation
thus add an extra layer of control to the already specific
activation events of the classical and lectin pathways.
Notably, in the case of the spontaneous activation of
the alternative pathway, the regulators entirely determine
the specificity on the basis of the recognition of so-called
host-associated molecular patterns (HAMPs), a phenom-
enon termed ‘‘reverse recognition.’’17 Importantly, activa-
tion of complement is also tightly regulated in time
and space by a very short half-life of activated C3 and
C4; i.e., these activated components have a limited
diffusion range because of quenching by water, ensuring
that only surfaces nearby the site of activation are
targeted.182011
Figure 2. The Lectin Pathway
(A) The lectin pathway components. Over-
view of the five different recognition
proteins of the lectin pathway, their tissue
and humoral localization, and their ligand
patterns. They all associate with MASPs
and MAps, except for CL-K1, which has
so far only been reported to associate
with MASP-1/MASP-3 and is not yet
known to activate complement. A sche-
matic drawing of the structural subunit of
each protein is shown, composed of three
identical polypeptide chains forming
a collagen-like helix with the recognition
domains extending in the C-terminal end.
(B) Figure showing the binding of MBL in
complex with MASP-2 to a molecular
pattern on the surface of a Gram negative
bacterium. MBL (and similarly the ficolins
and CL-K1) are multimers (here a tetramer
is shown) of the structural subunit drawn
in part A of this figure. These molecules
thus wield many recognition sites as
indicated on the figure. MASP-2 is a homo-
dimer and the domains are indicated with
the disulphide bridge connecting the
A- and B-chains after activating cleavage
in the activation peptide. MASP-2 then
activates C4 resulting in deposition of
C4b on the surface, which initiates the
tagging of the bacterium for phagocytosis.
The complement cascade may then prog-
ress as indicated in Figure 1.Conventional Genetic Deficiencies of Complement
Components
Experiments with genetically engineered complement-
deficient mice have been useful in research on the comple-
ment system. However, in general, inbred mouse strains
display poor complement activity,19 and numerous suscep-
tibility differences exist between mouse and man. The
study of individuals with increased susceptibility to
a variety of clinical symptoms, including suspect immuno-
deficiency, has proven to be a most important source of
information about defects of (and thus function of) the
human complement system. In the following, we focus
on recessive complement deficiencies based on complete
absence of components or functionally defective compo-
nents. The significance of partial deficiencies is less clearThe American Journal of Humanbut may be of relevance in some situ-
ations. With regards to genetic associ-
ation studies based on polymor-
phisms, we refer to recent reviews.
As a primer to such studies, strong
associations between SNPs in the
gene encoding factor H (CFH [MIM
134370, 609814]) and age-related
macular degeneration (AMD [MIM
610698]) have been identified.20–22
Polymorphisms in genes encoding
other members of the complement
system, e.g., factor B (CFB [MIM138470]) and C3 (C3 [MIM 120700, 613779]), have also
been associated with AMD.23,24 Studies are underway
with regards to treatment regimens involving restoration
of control mechanisms in this condition. Another example
is the finding in atypical hemolytic uremic syndrome
(aHUS [MIM 235400]) of a number of ‘‘loss-of function’’
polymorphisms in CFH and CD46 (encoding membrane
cofactor protein, MCP or CD46 [MIM 120920]) and
‘‘gain-of-function’’ polymorphisms in CFB.25
The prevalence of inherited complement deficiencies is
difficult to estimate because most deficiencies may be
caused by numerous different mutations in the relevant
gene. Furthermore, deficiency is only revealed when by
chance the physician or clinician decides that the symp-
toms of the patient warrant examination of the possibleGenetics 88, 689–705, June 10, 2011 691
Table 1. Conventional Complement Deficiencies
Protein Gene symbol MIM ID Cases / Homozygosity Disease Associations References
Recognition Proteins
MBL MBL2 154545 5% infections in
immunocompromised
individuals
28,106–108
H-ficolin FCN3 604973,
613860
3 immune deficiency,
necrotizing enterocolitis
40,41
C1q C1QA,
C1QB,
C1QC
120550,
120570,
120575,
613652
43 SLE-like syndrome, recurrent
bacterial infections
26,33,51
Enzymes
MASP-2 MASP2 605102 9 immune deficiency 37,38
C1r/s C1R,
C1S
613785,
120580,
613783,
216950
19 SLE-like syndrome, recurrent
bacterial infections
26,51
C2 C2 613927,
217000
1:20,000 autoimmune disease 28,32
Factor D CFD 134350,
613912
<10 meningococcal and
encapsulated bacterial
infections
26
Factor I CFI 217030,
610984
31 encapsulated bacterial
infections
109,110
Structural Proteins
C3 C3 120700,
613779
27 bacterial infections, SLE-like
syndrome
111,112
C4 C4A,
C4B
120810,
120820
26 SLE-like syndrome,
encapsulated bacterial
infections
33,51
C5 C5 120900,
609536
40 meningococcal infection 113,114
C6 C6 217050,
612446
>50 meningococcal infection 115–117
C7 C7 217070,
610102
>50 meningococcal infection 116,118,119
C8 C8A,
C8B,
C8G
120950,
120960,
120930,
613790,
613789
>50 meningococcal infection 120
C9 C9 120940,
613825
1:1,000 (Japan) meningococcal infection 46
Control Proteins
Properdin CFP 300383 >50 meningococcal infection 43
Factor H CFH 134370,
609814
27 hemolytic uremic syndrome
(HUS), dense deposit disease
111,121,122
C1-INH SERPING1 606860 1:50,000 hereditary angioedema (HAE) 33,123
CD11a (LFA-1),
CD11b (CR3),
CD11c (CR4)
/CD181
ITGAL,
ITGAM,
ITGAX,
ITGB2
153370,
120980,
151510,
600065,
116920
1:1,000,000 leukocyte adhesion deficiency
type I (LAD I)
124,125
CD46 (MCP) CD46 120920 atypical hemolytic uremic
syndrome (aHUS)
25,126,127
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Table 1. Continued
Protein Gene symbol MIM ID Cases / Homozygosity Disease Associations References
CD55,
CD59
(PIGA)2
CD55,
CD59,
PIGA
125240,
107271,
612300,
311770,
300818
1:1,000,000 paroxysmal nocturnal
hemoglobinuria (PNH)
128
Summary of reported cases of homozygosity for complement-system gene mutations leading to functionally deficient proteins. The proteins in question are given
on the left, followed by the gene symbol, the MIM ID number (associated with the gene and/or disease), the number of cases or incidence of homozygosity, and
associated clinical findings. The numbers in the last column refer to reviews in whichmost of the original literature is mentioned or to recent case reports where the
literature is discussed. Large ethnical differences are seen for C5, C6, C7, C8, and C9 deficiencies; for example, much higher frequencies of C9 deficiency in Japan
as compared to people in western Europe. As is evident, most cases of homozygosity are rare; i.e., below 50 cases. Some are marked ‘‘>50,’’ which indicates more
than 50 but less than 200 cases.1 Concomitant loss of LFA-1, CR3, and CR4 is due to loss of the common CD18 chain.2 Please note that PNHmay be caused either
directly by a mutation in CD59 or by loss of PIGA function leading to a secondary loss of CD55 and CD59.involvement of the complement system. As an example,
the prevalence of C2 deficiency is fairly well known in
southern Sweden because researchers at Lund University
have an interest in the complement system. The clinical
conditions most frequently associated with complement
defects are cases of hereditary angioedema (HAE [MIM
106100]), systemic lupus erythematosus (SLE [MIM
152700]), and recurrent meningococcal infection.1,26–28
But because it is a multifunctional system and due to
redundancies in immune defense mechanisms, the
frequency of complement deficiencies in other patient
groups is likely underestimated.
Many inherited complement deficiencies have been
revealed through association with invasive bacterial
infections. This susceptibility appears to be restricted to
a limited spectrum of bacteria, mainly encapsulated
bacteria. The reason is not clear, but many bacteria (e.g.,
Streptococcus pyogenes, Staphylococcus aureus, Helicobacter
pylori, and Pseudomonas aeruginosa) and several other
microorganisms29 have evolvedmechanisms to counteract
the activities of the complement system and are thus less
likely to be associated with complement deficiency.
It is interesting that the strongest disease-susceptibility
gene candidates for the development of SLE are found
within members of the classical pathway of complement
activation. This is speculated to be due to impaired
immune complex handling and inefficient clearance of
apoptotic cells in such patients.30 An alternative model
has been presented in which complement—together with
other components of the innate immune system—partici-
pates in the ‘‘presentation’’ of SLE-inducing self-antigens
to developing B cells. In this model, the complement
system and innate immunity protect against responses to
SLE (self) antigens by enhancing the elimination of self-
reactive lymphocytes.31 Homozygous deficiency of C1q is
very strongly associated with a lupus-like disease with
rash and glomerulonephritis. More than 90% of C1q-defi-
cient individuals were reported to have such symptoms.30
However, C1q deficiency appears to be very rare (Table 1),
and out of all cases of SLE only a tiny fraction are associated
with complement deficiency, indicating that SLE is a highly
multifactorial disease.The AmeC4 deficiency is also extremely rare, with only 26 cases
having been reported. This could be due to variation in
C4 gene copy number. Because two to seven copies are
found in the diploid genome, multiple mutations have to
occur for deficiency to result.
Deficiency of C2, which is nearly always due to a 28 bp
deletion in C2 (MIM 613927, 217000), occurs at higher
frequency; for example, there are probably more than
450 in a population of 9 million in Sweden.32 But whereas
the majority of patients with deficiencies of C1 or C4
develop SLE, the association of SLE with C2 deficiency is
much weaker.30 Deficiency of C2 is, on the other hand,
generally associated with a slight increase in the preva-
lence of autoimmune disease. Furthermore, about half
of the patients identified as having C2 deficiency had
a history of invasive infection with encapsulated bacteria.
However, family members lacking C2 but not showing
clinical symptoms were often encountered. A recent
review33 provides a detailed picture of the C1q, C2, and
C4 deficiencies described above.
With regards to the lectin pathway, MBL deficiency has
a surprisingly high prevalence. About 5% of people of
European descent show MBL deficiency when it is defined
as having a protein level less than 100 ng/ml. The
frequency is about twice this in Sub-Saharan Africans.
MBL-deficient adults appear healthy, but low levels of
MBL are associated with increased risk of infection in
toddlers,7 in cancer patients undergoing chemotherapy,
and in organ-transplant patients receiving immuno-
suppressive drugs, especially recipients of liver trans-
plants.34,35 The deficiency is due to homozygosity for
one of three quite common nonsynonymous SNPs in
the coding region ofMBL2 (MIM 154545) (gene frequency
in people of European descent: 0.14), as well as a pro-
moter polymorphism (gene frequency: 0.20).36 A case of
MASP-2 deficiency was originally described in an immuno-
deficient patient with autoimmune manifestations.37
The deficiency was due to homozygosity of a missense
mutation giving rise to a nonfunctional protein and
resulting in a very low MASP-2 level. Additional studies
revealed that the allele occurs in the general population
at a frequency suggesting homozygosity in approximatelyrican Journal of Human Genetics 88, 689–705, June 10, 2011 693
6 in 10,000 individuals, but only a low clinical penetrance
of MASP-2 deficiency is seen.38,39 Three cases of H-ficolin
deficiency have been described, two in neonates with
necrotizing enterocolitis40 and one in an adult with mixed
symptoms of immunodeficiency.41 All were due to a frame-
shift mutation occurring at a gene frequency of 0.011
among suspected immunodeficient patients as well as
among controls.
With regards to deficiency in proteins of the alternative
pathway, factor D deficiency, which is very rare (fewer than
10 cases reported42), and properdin deficiency both result
in selective impairment of the alternative pathway.32
In both cases meningococcal disease is the cause for inves-
tigating the complement system, and indeed this bacte-
rium is the most prevalent infectious agent in factor-
D-deficient individuals. Properdin deficiency is inherited
in an X-linked manner and is found as absence of the
protein or as a dysfunctional protein.43 In some families
with properdin deficiency, fulminant meningococcal
infections, particularly meningococcal meningitis, were
the most frequent problem encountered. Considering the
complement system as a general antimicrobial defense
system, it is surprising that susceptibility to other bacteria
is not evident. Associations of factor D or P deficiency with
autoimmune diseases have not been reported.
Inherited deficiency of the central component, comple-
ment factor C3, is very rare (27 cases reported), but when
identified it has been found in patients with life-threat-
ening infections with encapsulated bacteria.28 C3 defi-
ciency is also seen secondary to genetic deficiency of regu-
latory proteins of the alternative pathway. Lack of factor I
and of factor H thus leads to uncontrolled complement
activation and consumption of C3. aHUS has been associ-
ated with mutations in the genes encoding factor H and
factor I leading to failure of regulation of the alternative
pathway.44 This disorder is characterized by hemolytic
anemia, thrombocytopenia, and acute renal failure, which
is probably caused by uncontrolled activation of the
complement system at the renal endothelium.
Deficiencies in the terminal MAC components are typi-
cally identified in patients with recurrent invasive infec-
tions caused by N. meningitidis and N. gonorrhoeae.45
However, deficiencies of proteins in the MAC may remain
undetected until old age, if at all detected. Deficiencies
have been observed in all of the MAC components, C5,
C6, C7, and C8, at a very low frequency in European pop-
ulations (Table 1). There are large differences among
ethnicities, and the highest frequency is found in Japan,
where 1 in 1000 individuals are C9 deficient (due to a non-
sense mutation).46 This high frequency may even indicate
an advantage of MAC deficiency under certain conditions.
There seems to be no association between MAC deficiency
and autoimmune diseases.
Studies on the genes encoding regulatory complement
components have revealed a number of interesting find-
ings. HAE, resulting from C1 inhibitor (C1-INH) defi-
ciency, is an autosomal-dominant disorder characterized694 The American Journal of Human Genetics 88, 689–705, June 10,by recurrent episodes of angioedema with abdominal
attacks. The incidence of HAE is approximately 1:50,000,
with no ethnicity-based differences. C1-INH is a serine
protease inhibitor of the serpin family, named after its
inhibitory activity toward the C1 enzymes, C1r and C1s,
but it also controls the MASPs of the lectin pathway.
However, the angioedema is due to loss of control of
kallikrein of the contact system and is not a consequence
of failure of control of the classical or the lectin pathway.
The attacks frequently lead to hospitalization and are asso-
ciated with a substantial mortality. Two forms of hereditary
angioedema are found: type I (85% of cases), characterized
by low levels and low functional activity of C1-INH, and
type II, characterized by normal levels of C1-INH but
low functional activity. Both types are due to mutations
in SERPING1 (MIM 606860), encoding C1-INH. The
genetics and therapy of C1-INH deficiency (using C1-INH
purified from donor plasma) was recently reviewed by
Cugno et al.47
Two of the important membrane-bound inhibitors of
the complement system, decay-accelerating factor (DAF,
CD55) and membrane inhibitor of reactive lysis (MIRL,
CD59), are tethered to the cell surface through a glycosyl
phosphatidylinositol (GPI) anchor. Rare mutations (1 in
1,000,000) in PIGA (MIM311770), encoding phosphatidyl-
inositol glycan class A, which is involved in GPI produc-
tion, thus lead to loss of these regulators. This results
in paroxysmal nocturnal hemoglobinuria (PNH [MIM
300818]) because the complement system autoattacks the
erythrocytes lacking the control proteins. Such patients
can be treatedwith compounds inhibiting the complement
system, such as anti-C5 antibody.48 Direct mutations in
CD59 (MIM107271) can similarly result inCD59deficiency
(MIM 612300), causing PNH.
Deficiency of complement receptors may also cause
pathology, as seen in the case of leukocyte adhesion defi-
ciency (LAD) type I (MIM 116920), an autosomal-recessive
disorder of leukocyte function resulting from a deficiency
of the beta-2 integrin subunit (CD18, encoded by ITGB2
[MIM 600065]) of the CD11/CD18 complex.49,50 The
CD11/CD18 complex is important in adhesion and phago-
cytosis. Three CD11 alpha chains, CD11a (integrin alpha-
L, encoded by ITGAL [MIM 153370]), CD11b (integrin
alpha-M, encoded by ITGAM [MIM 120980]), and CD11c
(integrin alpha-X, encoded by ITGAX [MIM 151510]),
form heterodimer transmembrane complexes with the
CD18 beta chain: CD11a/CD18 (lymphocyte function-
associated antigen 1, LFA-1), CD11b/CD18 (complement
receptor 3, CR3), and CD11c/CD18 (CR4). Thus, CD18
deficiency results in a combined loss of expression of
LFA-1, CR3, and CR4, causing defects in neutrophil,
macrophage, T cell, and B cell adhesion to the vascular
endothelium and inefficient migration into infectious
sites, as well as impairment of normal Tcell and B cell func-
tions.51 Clinically, LAD is characterized by recurrent bacte-
rial infections and impaired pus formation and wound
healing.522011
We have summarized these conventional complement
deficiencies in Table 1. Investigations of more and larger
groups of patients are expanding our understanding of
the role of complement in disease. Young patients with
invasive infections caused by encapsulated bacteria should
be screened for complement deficiency. As evident from
recent findings in studies on gene associations with
AMD, surprising angles on the clinical importance of the
complement system may be found through the analysis
of other patient groups. Although the association of, for
example, factor H deficiency with AMD fits its role in
complement-mediated reactions, genetic analyses have
now revealed completely unexpected roles of complement
components beyond the hitherto known functions of the
complement system.
Unexpected Roles of Proteins of the Lectin Pathway
of Complement
In a recent study in this journal, Sirmaci and colleagues
harnessed the power of homozygosity mapping and
next-generation exome sequencing to identify a novel
missense mutation in the exon encoding the serine
protease domain of the protein MASP-3 (mannan-binding
lectin-associated serine protease 3) in a family afflicted by
the autosomal-recessive 3MC syndrome.53 The 3MC
syndrome is a term encompassing the overlappingMingar-
elli (MIM 265050),54 Malpuech (MIM 248340),55 Michels
(MIM 257920),56 and Carnevale (also MIM 265050)57
syndromes, which were independently described but
appear clinically to be unified58 and, as will be clear,
have underlying mutations and etiology that now appear
to be unified as well. Patients with 3MC syndrome (see
Figure 1 in 53) may exhibit a spectrum of developmental
features, including developmental delay, growth and
mental retardation, and characteristic facial dysmorphism,
such as hypertelorism, telecanthus, blepharophimosis,
blepharoptosis, and epicanthus inversus. They may also
suffer from anterior-chamber eye anomalies, mixed hear-
ing loss, cleft lip and/or palate, periumbilical defects, and
skeletal anomalies with radioulnar synostosis and caudal
appendage.
MASP-3, MASP-1, and MAp44 are all encoded byMASP1.
Sirmaci and colleagues proceeded to identify a nonsense
mutation in a part of MASP1 (MIM 600521) common
to all three splice variants in an unrelated family with
3MC syndrome. Thus, a novel and unexpected role was
discovered of what was so far regarded ‘‘only’’ as a comple-
ment component. A more recent paper by Rooryck and
colleagues presented an independent confirmation of
this finding and also demonstrated 3MC-causing muta-
tions in another gene, COLEC11 (MIM 612502), encoding
a protein, collectin kidney 1 (CL-K1 or collectin-11), of the
same innate immune defense system, the lectin pathway
of complement activation.59 Their studies on zebrafish
further support the developmental influence of mutations
in these two genes, as morphant fish showed severe cranio-
facial abnormalities. Importantly, this finding also indi-The Amecates the presence of an evolutionarily conserved pathway
of embryogenesis. In the following, we will give a more
detailed description of the proteins encoded by COLEC11
and MASP1 and their suggested function.
CL-K1
Asmentioned above, CL-K1 is a recently describedmember
of the collectin family of humoral pattern-recognition
molecules.10,11 So far, only two papers have been directed
at describing this protein. The evidence for its function
in the innate immune defense and in the complement
system is only fragmentary and is largely deduced from
structural similarities with MBL and ficolins (Figure 2A).
These molecules are composed of subunits consisting of
three identical polypeptides with a collagen region and
a C-terminal carbohydrate-recognition domain (CRD).
Three or more subunits are joined into oligomers forming
collagen-like coiled regions. Dimers of MASPs associate
with the collagen region and mediate complement activa-
tion when MBL or ficolins bind to their targets (Figure 2B).
It appears that CL-K1, composed of 34 kDa polypeptides
with a collagen region and a C-type CRD, must present
a similar overall structure (Figure 3), and it seems also to
associate with MASPs11 and to bind to a number of micro-
bial polysaccharides.10 The synthesis of CL-K1 is widely
distributed in the body, and, like MBL and ficolins, it is
secreted and circulates in the blood.
The CL-K1-Encoding Gene, COLEC11
COLEC11, encoding CL-K1, is located on chromosome 2,
at 2p25.3. It spans about 50 kb and encodes two splice
forms (Figure 3). Transcript variant 1 comprises 7 exons
(1–3, 5–8) and 1320 nt. Transcript variant 2 is 8 exons
(1–8) and 1399 nt long. The resulting isoforms a and
b are 271 aa and 268 aa long, respectively. Isoform a is pre-
dicted by SignalP60 to contain a signal peptide (aa 1–25),
whereas isoform b does not harbor a signal peptide and
cleavage motif. The existence of both isoforms at the
mRNA level is well supported by expressed sequence tags
(ESTs). At the protein level, the secreted isoform a of
CL-K1 is the form described in the literature. It has 24 Gly-
Xaa-Yaa repeats, starting at aa position 41, constituting
a collagen-like stalk, and a C-terminal CRD (aa 151–266),
thus identifying it as a member of the collectins (Figure 3).
The MASPs
The MASPs are modular proteases composed of well-
described domains in the order CUB-EGF-CUB-CCP-CCP-
SP (Figure 2B and Figure 4). The CUB (C1r/C1s, embryonic
sea Urchin protein [Uefg], and Bone-morphogenetic
protein 1 [Bmp1]) domain is around 110 aa and is found
in a diverse set of proteins involved mainly in develop-
mental processes.61 The EGF (epidermal growth factor)
domain of approximately 50 aa is also found in many
proteins and is known to mediate protein-protein interac-
tions. The CUB and EGF domains of the MASPs are respon-
sible for dimerization and for the calcium-dependentrican Journal of Human Genetics 88, 689–705, June 10, 2011 695
Figure 3. Gene Structure, Alternative Splicing, and Protein Products of COLEC11
(A) Overview of the gene/primary transcript and the two suggested alternative splice variants. Mutually exclusive splice events are indi-
cated by the dotted lines. Greyed areas indicate the 50 and 30 UTRs. Notice the predicted use of alternative translation initiation sites in
isoforms a and b.
(B) The protein structure of the secreted isoform is illustrated and polymorphisms are indicated, along with the mutations reported by
Rooryck et al. The exact locations of the mutations are: c.496T>C (p.Ser169Pro), c.610G>A (p.Gly204Ser), c.45delC (p.Phe16SerfsX85),
c.648_650delCTC (p.Ser217del), and c.300delT (p.Gly101ValfsX113), as well as the 27 kb exon 1–3 deletion. The formation of the struc-
tural subunit composed by three identical polypeptide chains and the ensuing oligomerization is illustrated.binding to MBL and ficolins.62–64 The CCP (complement
control protein) domains of around 60 aa are found in
a number of complement factors and other proteins.65
The contiguous CCPs of MASP-1 and MASP-2, especially
the second CCP domain, have been implicated in the
binding of macromolecular substrates.66–71 Finally, the SP
(serine protease) domain is the catalytically active unit of
the proteases and defines them as part of the S1A family
of chymotrypsin-like proteases. The second CCP domain
and the SP domain are connected by a somewhat flexible
activation peptide, which lies just upstream of a site, which
is cleaved upon activation of the MASP (Figure 4).
MASP1
MASP1 is located on chromosome 3q27-28 and gives rise to
three alternative splice products: MASP-1, MASP-3, and
MAp44 (Figure 4).12,13,72,73 The gene encompasses 18
exons, of which the first 8 exons plus exons 10 and 11
encode the five N-terminal domains shared by MASP-1696 The American Journal of Human Genetics 88, 689–705, June 10,andMASP-3, CUB-EGF-CUB-CCP-CCP. The serine protease
domainofMASP-1 is encodedby six separate exons (13–18),
whereas for MASP-3 it is encoded by a single exon
(12)12,74,75 (Figure 4). ThusMASP-1 andMASP-3 share their
first five domains but have distinct serine protease domains
(Figure 4). The third splice product, encoding MAp44, is
composed of nine exons: the first eight exons are shared
with MASP-1 and MASP-3, and they encode the first four
domains, CUB-EGF-CUB-CCP, whereas the ninth exon is
unique to MAp44 (Figure 4). An additional adenosine
nucleotide from exon 8 combined with the first 50 nt of
exon 9 encodes the unique 17 C-terminal aa of MAp44.
In addition to the three expressed splice products,
a fourth splice variant has been recorded in the NCBI
database. However, the RNA arising from this splice
pattern does not constitute mRNA, but is predicted to be
degraded by the nonsense-mediated mRNA decay (NMD)
pathway.76 The fourth splice variant is identical to MASP-3
mRNA, save for the exclusion of exon 2, giving rise to2011
Figure 4. Gene Structure, Alternative Splicing, and Protein Products of MASP1
(A) Overview of the gene or primary transcript and the four resulting alternative splice variants. MAp44, MASP-1, and MASP-3 arise by
mutually exclusive differential splicing (indicated by the dotted lines), each product having its own 30 UTR and poly A signal. A fourth
splice product is very similar to MASP-3 mRNA, but with the exclusion of exon 2. This leads to a frameshift, and the product is predicted
to be degraded by nonsense-mediated decay.
(B) Overview of the resulting protein structures of the three mRNAs produced fromMASP1. The arrow indicates the cleavage site for the
signal peptide. Nonsilent polymorphisms are indicated (in black), along with the mutations reported by Sirmaci et al. (in red) and by
Rooryck et al. (in green). The exact locations of the indicated nonsilent polymorphisms and mutations are given in Table 2. The part
of the polypeptide chain common to all three proteins, as well as the part common to MASP-1 and MASP-3, is indicated.a premature termination (nonsense) codon. Whether this
RNA splice product is truly a ‘‘waste product’’ or whether
it is a ‘‘regulatory product’’ of controlled splice patterns is
unknown. In this context it is exciting to note that in
the recent report of the ‘‘splicing code,’’ a class of exons
were detected whose inclusion silenced expression in
adult tissues by activating nonsense-mediated messenger
RNA decay. Exclusion of such exons, on the other hand,
promoted expression during embryogenesis.77 Of course,
in the case ofMASP1, it seems that it is rather the exclusion
of an exon that drives generation of a transcript, which is
subject to NMD. Nonetheless, these findings point to the
importance of regulated alternative splicing events on
a genome-wide scale, and one may speculate that MASP1
is also subject to such regulation.
The CL-K1 Gene and 3MC
Rooryck and colleagues aimed to identify causative
mutations in one or more genes in 3MC syndrome by
homozygositymapping in a total of 11 families and discov-The Ameered two regions of homozygosity shared by affected indi-
viduals.59 Four families were initially identified, and they
shared a homozygous region of 2.2 MB on 2p25.3.
Sequencing revealed two homozygous nonsynonymous
mutations (c.496T>C, c.610G>A), one single-base
deletion (c.45delC), and one in-frame deletion (c.648_
650delCTC) in COLEC11, encoding CL-K1 (resulting in,
respectively: p.Ser169Pro, p.Gly204Ser, p.Phe16SerfsX85,
and p.Ser217del) (Figure 3). Subsequent sequencing of
COLEC11 in other 3MC patients revealed two additional
mutations in two previously described probands. The first
was a dramatic 27 kb homozygous deletion encompassing
exons 1–3 of COLEC11 (exon 1–3 deletion), the second
a homozygous single-base deletion causing a frameshift
and premature stop codon (c.300 delT, resulting in
p.Gly101ValfsX113) (Figure 3).
The two single-nucleotide deletions dictating frame-
shifts and premature termination, as well as the 27 kb
deletion, are obviously detrimental. The in-frame deletion
resulting in loss of a single amino acid and the two aminorican Journal of Human Genetics 88, 689–705, June 10, 2011 697
acid substitutions all occur in the CRD of CL-K1. These are
otherwise well-conserved residues, and none of the muta-
tions were found in 368 ethnically matched controls or
in the dbSNP or 1000 Genomes databases. Indeed, no
CL-K1 was found in the serum of two patients with the
p.Gly204Ser mutation.59
Analysis of the localization of the protein in the mouse
revealed broad tissue distribution during embryogenesis.
This was also found by in situ expression analyses in zebra-
fish. The effect of loss of function of this protein during
zebrafish embryogenesis was examined by the use of
morpholinos directed against the initiation site and the
exon 2-intron 2 splice site. Notably, these morpholinos
target both isoforms. There were evident differences in
the craniofacial skeleton compared with uninjected or
control morpholino-injected embryos. Importantly, it was
found that thephenotypeofCOLEC11morphantfishcould
be rescued by coinjecting embryos with the full-length
human CL-K1 mRNA.
MASP1 Mutations and 3MC Syndrome
A large number of SNPs have been reported forMASP1, but
until now, no mutations with impact on the function of
either of the three protein products have been reported.
An overview of the nonsilent polymorphisms from dbSNP
as well as those reported by Sirmaci and colleagues and
Rooryck and colleagues is given in Table 2. The fact that
two completely different mutations were found by Sirmaci
and colleagues in two independent families, and that
three additional mutations were found independently by
Rooryck and colleagues in another four families, lends
credibility to the conclusion that MASP1 dysfunctionality
is causative of the phenotype. One of the mutations iden-
tified by Sirmaci and colleagues is a nonsense mutation in
the common part of the three alternative splice products
(Figure 4). However, it would appear that MASP-3 is the
central product, as this is the only component affected in
the other family as well as the four families reported by
Rooryck and colleagues. The affected residue in the
MASP-3-specific mutation of Sirmaci et al., G687, is located
within the active site close to the junction of two b-barrels
and in close proximity to D658 (Figure 4). On the basis of
structural modeling, Sirmaci and colleagues present the
elegant hypothesis that given the close proximity of
D658 to G687, the G687R variant would likely result in
the formation of an intermolecular salt bridge, thereby
inhibiting catalytic activity.53 Indeed, Asp658 in MASP-3
corresponds to Asp189 in chymotrypsin (c189, chymo-
trypsin numbering used in the following for reference),
and this residue is responsible for primary substrate speci-
ficity in the chymotrypsin family. InMASP-1, the side chain
of Arg677 (c224) is rotated toward the Asp640 (c189) and
forms a salt bridge, which competes with the S1-P1 interac-
tion upon substrate binding.78 This is envisioned to modu-
late the activity ofMASP-1. Thus, it seems plausible that the
reported mutation in the MASP-3-specific exon could simi-
larly disrupt or suppress the protease activity.698 The American Journal of Human Genetics 88, 689–705, June 10,The three mutations identified by Rooryck and
colleagues are all located in the MASP-3-specific exon
(Figure 4). They find two homozygous missense mutations
in two new 3MC families (c.1489C>T and c.1888T>C, at
the protein level resulting in p.His497Tyr and p.Cy-
s630Arg, respectively) and a third homozygous missense
mutation in two previously described 3MC families
(c.1997G>A, encoding p.Gly666Glu). All of these muta-
tions are found in well-conserved positions, are predicted
to be damaging (Polyphen), and are not found in 286
ethnically matched controls.59
Rooryck et al. targeted MASP1 expression in developing
zebrafish embryos by use of morpholinos specific for the
initiation site and the exon 3-intron 3 splice site.59 Such
targeting should disrupt expression of the two splice forms
(MAp44 and MASP-3), which are predicted to be found in
zebrafish.13 Pigment and craniofacial cartilage defects
similar to those seen in CL-K1 morphants resulted.
MASP-3 and CL-K1 Likely Act in the Same Pathway, Possibly as
Chemoattractants
Rooryck and colleagues stab at the mechanistic link by
examining the effects of COLEC11 and MASP1 mutations
on the migration of cranial neural crest cells during
zebrafish development. It appears that they may be early
guidance cues directing the migration of neural crest cells,
and this is followed up by the demonstration that recombi-
nant CL-K1 attracts neural crest cells. The effect of CL-K1
was confirmed in a quail neural tube explant assay.59 Other
proteins with collagen-like regions linked to a CRD
domain (surfactant protein D79–81 and surfactant protein
A82) have previously been noted to act as chemoattrac-
tants. Whereas the possibility remains that several
members of this family have dual roles in immunity and
development, the observed directional cell movement
may be caused by a ‘‘matrix-like’’ effect of the collagen
helix in the proteins, or, indeed, these molecules may acti-
vate cells to secrete other chemoattractants.
Notwithstanding the zeal of the investigators, the mech-
anism behind the link between MASP1 and COLEC11
mutations and 3MC syndrome remains obscure. Sirmaci
and colleagues speculate that the effect may be mediated
through an activity of MASP-3 toward insulin-like growth
factor-binding protein 5 (IGFBP-5).53 This is based on one
study demonstrating cleavage of IGFBP-5 by MASP-3.83
However, such an activity has not been firmly established,
but is based on the observation of a weak activity of
recombinant serine protease domain of MASP-3 toward
IGFBP-5. IGFBP-5-cleaving activity has also been reported
for a number of other enzymes; for example, thrombin,84
C1s,85 and the inflammation-related neutrophil proteases
cathepsin G and elastase,86 all of which are serine proteases
involved in or related to host defense. It is tempting to
suggest a function in the release of sequestered IGF for
promotion of wound healing and repair. A more cynical
explanation, based on the large number of reported
IGFBP-5 proteases,87 is that IGFBP-5 is a quite promiscuous2011
Table 2. Overview of the Nonsilent Polymorphisms in the Coding Parts of MASP1 and the Resulting Amino Acid Substitutions
Chr. Position Coding Pos. dbSNP rs #/Ref. Heterozygosity Contig Ref. Missense Amino Acid Contig Ref. Substitution
Common
187003844 6 rs116384821 N.D. G T 2 Arg [R] Ser [S]
187003788 62 rs1062049 0.005 C T 21 Thr [T] Ile [I]
187003786 64 rs77189011 0.022 G A 22 Val [V] Met [M]
186980367 379 rs115647447 N.D. C T 127 Arg [R] Cys [C]
186978610 466 rs78137557 0.236 T C 156 Tyr [Y] His [H]
186978589 487 rs115241263 N.D. G A 163 Gly [G] Ser [S]
186974493 703 rs3203210 N.D. G C 235 Glu [E] Gln [Q]
186974465 731 rs28945071 N.D. A G 244 Tyr [Y] Cys [C]
186971076 772 rs866085 N.D. C G 258 Pro [P] Ala [A]
186970985 863 rs116001173 N.D. G A 288 Arg [R] Gln [Q]
186970978 870 Sirmaci et al., 20101 N.D. G A 290 Trp[W] Stop[X]
186970964 884 rs73886128 N.D. G A 295 Arg [R] Lys [K]
MAp44
186965162 1102 rs113938200 N.D. G A 368 Asp [D] Asn [N]
MASP-1/3
186959343 1229 rs114365879 N.D. G A 410 Gly [G] Asp [D]
186959295 1277 rs28945068 0.034 G A 426 Gly [G] Glu [E]
MASP-3
186954170 1489 Rooryck et al., 20117 N.D. C T 497 His [H] Tyr [Y]
186954107 1552 rs73068950 N.D. G A 518 Val [V] Ile [I]
186953975 1684 rs72549155 0.010 C G 562 Pro [P] Ala [A]
186953932 1727 rs72549154 0.058 G T 576 Arg [R] Met [M]
186953906 1753 rs111908734 N.D. C A 585 His [H] Asn [N]
186953812 1847 rs2461280 N.D. T C 616 Val [V] Ala [A]
186953771 1888 Rooryck et al., 20117 N.D. T C 630 Cys [C] Arg [R]
186953749 1910 rs115022399 N.D. G T 637 Arg [R] Leu [L]
186953662 1997 Rooryck et al., 20117 N.D. G A 666 Gly [G] Glu [E]
186953600 2059 Sirmaci et al., 20101 N.D. G A 687 Gly [G] Arg [R]
186953491 2168 rs115897757 N.D. A G 723 Glu [E] Gly [G]
MASP-1
186944222 1528 rs28945070 0.010 A G 510 Ser [S] Gly [G]
186943280 1573 rs28945073 N.D. C T 525 Arg [R] Trp [W]
186943150 1703 rs13322090 0.041 T C 568 Val [V] Ala [A]
186937924 2035 rs3774266 0.006 G A 679 Gly [G] Arg [R]
The polymorphisms are divided into those from the common part, the MAp44-specific part, the part common for MASP-1 and MASP-3, the MASP-3-specific part,
and the MASP-1-specific part (see Figure 4). The mutations reported by Sirmaci et al.1 and by Rooryck et al.7 are indicated in bold.substrate. The weak activity of MASP-3 could also be
explained as an evolutionary remnant on the basis of
homology with the proteases known to cleave IGFBP-5. It
would be worthwhile to examine whether mutated
MASP-3 is produced and whether it is indeed catalyticallyThe Ameactive or not. Unfortunately, the latter is difficult because
a convincing substrate forMASP-3 remains to be identified.
Notably, there exists a mouse that was targeted in exon
two of the MASP1 ortholog (masp1) and is hence (presum-
ably) deficient in MASP-1, MASP-3, and MAp44.88 It hasrican Journal of Human Genetics 88, 689–705, June 10, 2011 699
been reported to be more susceptible to influenza virus
infection, and more recently it was found that the mouse
is deficient in alternative pathway function, with MASP-1
reportedly being the enzyme responsible for activation
of murine factor D by cleavage of pro-factor D.89 Apart
from small size and low weight, no phenotypic character-
ization of the mouse has been presented. One would
have expected a murine ‘‘3MC’’ phenotype to be immedi-
ately apparent.
Evolutionary Aspects
MASPs are found all the way back to cephalochordates and
urochordates. MASP-2 and MASP-3 are believed to have
evolved from an ancestral MASP-1 by gene duplication
and divergence.72,90 In this connection, it is peculiar that
birds91 and fish seem to have no MASP-1, whereas they
have MASP-2 and MASP-3, but this could represent a loss
or inactivation of the MASP-1 exon(s) in each of their
ancestors subsequent to the duplication of MASP-1.92
Interestingly, the chicken also lacks the related hapto-
globin, which is believed to have evolved from an ancestral
MASP.93
Krem and colleagues created a large phylogenetic tree of
the protease domains of all the then-known members of
the S1 family.94 The tree was rooted with the use of marine
arthropod enzymes, chosen for the primordiality of the
species and certain molecular markers. This phylogenetic
tree suggested two origins of proteases that participate
in the innate immune system. Proteases of mast cells,
neutrophils, and other immune cells are most closely
related to kallikrein enzymes, which probably evolved
from an ancestral gene distinct from degradative, clotting,
and complement lineages.95,96 Complement proteases,
with the exceptions of factors D and I, share ancestry
with clotting proteases,97 most likely having evolved
from clotting-immune systems of the type found in the
horseshoe crab.98,99 Interestingly, complement and coagu-
lation proteases diverge in close relation to embryonic
developmental proteases. There are some functional over-
laps between arthropod developmental and hemolymph
proteases, and these evolutionary connections between
development, clotting, and immunity extend beyond the
proteases to their substrates.95 In the complement system
there is a clear distinction of origin between enzymes of
the classical/lectin and alternative pathways. Factor D
diverges early with enzymes of cell-mediated immunity
and shares common ancestry with arthropod degradative
enzymes. Factor I also groups with degradative enzymes,
but of later origin, whereas factors B and C2 diverge
together and share common ancestry with fibrinolytic
proteases. Finally, the MASPs, C1r, and C1s emerge in close
connection with enzymes of blood coagulation.95
Extending the Scope
Notably, the 3MC patients suffer moderate mental retarda-
tion. In recent years, evidence has been mounting of unre-
lated or alternative roles of complement outside immunity.700 The American Journal of Human Genetics 88, 689–705, June 10,In the mouse, Stevens and colleagues reported that the
classical complement cascade mediates CNS synapse elim-
ination100 and that consequently C1q knockout mice
display enhanced synaptic connectivity and suffer from
epilepsy.101 No neural defects have been reported in the
identified human C1q-deficiency cases. In contrast, the
finding of elevated levels of MBL/MASP-2 complexes
within the schizophrenic brain102 may implicate the lectin
pathway in neural functions in humans. A model
describing a possible mechanism for activity-dependent
synapse elimination was suggested nearly two decades
ago.103 According to this model, strong synapses facilitate
elimination of weaker synapses by sending both a protec-
tive signal for the stronger synapse, resulting in stabiliza-
tion and strengthening, and a punishment signal for
weaker synapses, resulting in their elimination. It has
recently been suggested that immune molecules may
mediate the punishment signals.104 Synapse elimination
is a prominent process both during development and
during neurodegenerative diseases and aging, in the
former as a requirement for correct formation of synaptic
networks and in the latter as a detrimental process destroy-
ing such synaptic networks. An intriguing hypothesis has
been proposed: that a common mechanism may underlie
this elimination of synapses during development and
disease.104 Indeed, a recent review has highlighted the
currently known roles, some detrimental and some protec-
tive, of complement in neurodegenerative disorders.105
The new results on MASP-3 and CL-K1 may spur renewed
interest in studies on intellect and the immune system.
Conclusion
A number of conventional complement deficiencies with
immunological consequences have been characterized.
Here, we have focused on recessive complement defi-
ciencies based on complete absence of components or
functionally defective components. Partial deficiencies
and polymorphisms also account for numerous immuno-
logical defects. Commonly, these conventional comple-
ment deficiencies have not been very severe since the
advent of antibiotics and modern treatment modalities,
and hence such genetic deficiencies are quite widespread
in various populations.
In contrast, newly discovered defects of components of
the lectin pathway have implications outside innate
immunity, namely in development. These appear to be
more severe and are caused by de novo mutations, which
have arisen in a handful of families and have been fixed
by consanguinity. A role for MASP-3 in developmental
processes is supported by several lines of circumstantial
evidence: (1) a general link between immunity and devel-
opment, (2) a specific evolutionary relationship between
complement and coagulation proteases and embryonic
developmental proteases, (3) broad expression of MASP-3
in developing chick and rat embryos,91 (4) enzymatic
activity toward IGFBP-5 and similar broad developmental
expression of this purported substrate, itself suggested to2011
be involved in developmental processes, (5) homology
with classical pathway proteases involved in develop-
mental processes in the mouse, (6) CUB-domain-contain-
ing proteins often being involved in developmental
processes,61 and (7) a very high degree of phylogenetic
conservation of MASP-3. The report by Sirmaci and
colleagues has provided the first solid evidence for an
important function of MASP-3. This finding is confirmed
and substantiated by the report of Rooryck and colleagues,
and it is extended with the discovery of a similar role for
CL-K1, as well as by the evidence that the two proteins
collaborate in the same pathway. Future studies should
elucidate the mechanism behind these fascinating obser-
vations.Acknowledgments
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